Ginkgo Bioworks Holdings Inc (NYSE: DNA) on Friday, soared 12.92% from the previous trading day, before settling in for the closing price of $10.22. Within the past 52 weeks, DNA’s price has moved between $5.26 and $66.00.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 104.75%. The company achieved an average annual earnings per share of 45.22%. With a float of $36.49 million, this company’s outstanding shares have now reached $41.37 million.
Let’s determine the extent of company efficiency that accounts for 1218 employees. In terms of profitability, gross margin is 63.73%, operating margin of -271.32%, and the pretax margin is -298.94%.
Ginkgo Bioworks Holdings Inc (DNA) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Ginkgo Bioworks Holdings Inc is 33.02%, while institutional ownership is 47.96%. The most recent insider transaction that took place on Jan 03 ’25, was worth 1,011. Before that another transaction happened on Jan 02 ’25, when Company’s Officer proposed sale 99 for $9.97, making the entire transaction worth $987.
Ginkgo Bioworks Holdings Inc (DNA) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 45.22% per share during the next fiscal year.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Trading Performance Indicators
Ginkgo Bioworks Holdings Inc (DNA) is currently performing well based on its current performance indicators. A quick ratio of 5.79 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.44.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -12.90, a number that is poised to hit -1.50 in the next quarter and is forecasted to reach -5.81 in one year’s time.
Technical Analysis of Ginkgo Bioworks Holdings Inc (DNA)
Looking closely at Ginkgo Bioworks Holdings Inc (NYSE: DNA), its last 5-days average volume was 1.4 million, which is a drop from its year-to-date volume of 1.8 million. As of the previous 9 days, the stock’s Stochastic %D was 71.85%. Additionally, its Average True Range was 1.13.
During the past 100 days, Ginkgo Bioworks Holdings Inc’s (DNA) raw stochastic average was set at 93.45%, which indicates a significant increase from 90.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 111.50% in the past 14 days, which was higher than the 111.23% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $8.81, while its 200-day Moving Average is $17.01. However, in the short run, Ginkgo Bioworks Holdings Inc’s stock first resistance to watch stands at $12.26. Second resistance stands at $12.99. The third major resistance level sits at $14.10. If the price goes on to break the first support level at $10.42, it is likely to go to the next support level at $9.31. Should the price break the second support level, the third support level stands at $8.58.
Ginkgo Bioworks Holdings Inc (NYSE: DNA) Key Stats
Market capitalization of the company is 748.98 million based on 57,479K outstanding shares. Right now, sales total 251,460 K and income totals -892,870 K. The company made 89,050 K in profit during its latest quarter, and -56,400 K in sales during its previous quarter.
